[{"id":"607c59af-1fd9-4afc-8491-e33c116441ac","acronym":"PNeoVCA","url":"https://clinicaltrials.gov/study/NCT05269381","created_at":"2022-03-08T17:52:43.258Z","updated_at":"2024-07-02T16:34:26.810Z","phase":"Phase 1/2","brief_title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05269381 - PNeoVCA","lead_sponsor":"Mayo Clinic","biomarkers":" KRAS • BRAF • ALK • TMB • MSI • ROS1 • NTRK","pipe":" | ","alterations":" TMB-H","tags":["KRAS • BRAF • ALK • TMB • MSI • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • Leukine (sargramostim) • neoantigen peptide vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/31/2022","start_date":" 03/31/2022","primary_txt":" Primary completion: 02/24/2025","primary_completion_date":" 02/24/2025","study_txt":" Completion: 02/24/2026","study_completion_date":" 02/24/2026","last_update_posted":"2024-06-12"}]